BR9911357A - Combinações terapêuticas de moduladores (seletivos) de receptor de estrogênio (serm) e secretagogos de hormÈnio de crescimento (ghs) para tratar fragilidade músculo-esqueletal - Google Patents
Combinações terapêuticas de moduladores (seletivos) de receptor de estrogênio (serm) e secretagogos de hormÈnio de crescimento (ghs) para tratar fragilidade músculo-esqueletalInfo
- Publication number
- BR9911357A BR9911357A BR9911357-0A BR9911357A BR9911357A BR 9911357 A BR9911357 A BR 9911357A BR 9911357 A BR9911357 A BR 9911357A BR 9911357 A BR9911357 A BR 9911357A
- Authority
- BR
- Brazil
- Prior art keywords
- fragility
- ghs
- serm
- modulators
- selective
- Prior art date
Links
- 102000015694 estrogen receptors Human genes 0.000 title abstract 2
- 108010038795 estrogen receptors Proteins 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000003324 growth hormone secretagogue Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- -1 4- (2-pyrrolidin-1-yl-ethoxy) -phenyl Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 abstract 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Patente de Invenção: <B>"COMBINAçõES TERAPêUTICAS DE MODULADORES (SELETIVOS) DE RECEPTOR DE ESTROGêNIO (SERM) E SECRETAGOGOS DE HORMÈNIO DE CRESCIMENTO (GHS) PARA TRATAR FRAGILIDADE MúSCULO-ESQUELETAL"<D>. Esta invenção refere-se a combinações de composições farmacêuticas e a métodos que contenham (-)-cis-6-fenil-5-(4-(2-pirrolidin-1-il-etóxi)-fenil)-5,6,7,8-tetrehidronaftale n-2-ol ou um seu sal farmaceuticamente aceitável e 2-amino-N-(1(R)-(2,4-difluoro-benziloximetil)-2-oxo-2-(3-oso-3a (R)-piridin-2-ilmetil)-2-(2,2,2-trifluoro-etil)-2,3,3a,4,6,7-hexahidro-piraz olo [4,3,-c] piridin-5-il)-etil)-2-metil-propionamida ou um seu sal farmaceuticamente aceitável, métodos para a utilização de tais composições e kits que contenham tais composições. As composições são úteis para o tratamento de fragilidade musculo-esqueletal, incluindo a osteoporose, a fratura osteoporótica, a fraca massa óssea, a fragilidade e a fraca massa muscular.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8942498P | 1998-06-16 | 1998-06-16 | |
| PCT/IB1999/000796 WO1999065488A1 (en) | 1998-06-16 | 1999-05-03 | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9911357A true BR9911357A (pt) | 2001-03-13 |
Family
ID=22217565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9911357-0A BR9911357A (pt) | 1998-06-16 | 1999-05-03 | Combinações terapêuticas de moduladores (seletivos) de receptor de estrogênio (serm) e secretagogos de hormÈnio de crescimento (ghs) para tratar fragilidade músculo-esqueletal |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1085867A1 (pt) |
| JP (1) | JP2002518328A (pt) |
| KR (1) | KR20010052817A (pt) |
| CN (1) | CN1305378A (pt) |
| AP (1) | AP9901581A0 (pt) |
| AR (1) | AR018868A1 (pt) |
| AU (1) | AU3342099A (pt) |
| BG (1) | BG105128A (pt) |
| BR (1) | BR9911357A (pt) |
| CA (1) | CA2335112A1 (pt) |
| CO (1) | CO5070586A1 (pt) |
| EA (1) | EA200001189A1 (pt) |
| GT (1) | GT199900083A (pt) |
| HR (1) | HRP20000857A2 (pt) |
| HU (1) | HUP0102395A2 (pt) |
| ID (1) | ID26726A (pt) |
| IL (1) | IL139587A0 (pt) |
| IS (1) | IS5727A (pt) |
| MA (1) | MA26648A1 (pt) |
| NO (1) | NO20006381L (pt) |
| OA (1) | OA11569A (pt) |
| PA (1) | PA8472101A1 (pt) |
| PE (1) | PE20000633A1 (pt) |
| PL (1) | PL345064A1 (pt) |
| SK (1) | SK18902000A3 (pt) |
| TN (1) | TNSN99118A1 (pt) |
| UY (1) | UY25557A1 (pt) |
| WO (1) | WO1999065488A1 (pt) |
| ZA (1) | ZA993973B (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1004306A3 (en) * | 1998-08-06 | 2000-06-07 | Pfizer Products Inc. | Estrogen agonists/antagonists |
| CA2420535A1 (en) * | 2000-08-30 | 2002-03-07 | Mary Tanya Am Ende | Sustained release formulations for growth hormone secretagogues |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| US7524866B2 (en) | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
| SI1460969T1 (sl) * | 2001-11-29 | 2008-10-31 | Gtx Inc | Preprečevanje in zdravljenje s pomanjkanjem androgena inducirane osteoporoze |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| ES2602789T3 (es) | 2007-02-09 | 2017-02-22 | Ocera Therapeutics, Inc. | Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
-
1999
- 1999-05-03 OA OA1200000346A patent/OA11569A/en unknown
- 1999-05-03 PL PL99345064A patent/PL345064A1/xx unknown
- 1999-05-03 WO PCT/IB1999/000796 patent/WO1999065488A1/en not_active Application Discontinuation
- 1999-05-03 EA EA200001189A patent/EA200001189A1/ru unknown
- 1999-05-03 BR BR9911357-0A patent/BR9911357A/pt not_active Application Discontinuation
- 1999-05-03 IL IL13958799A patent/IL139587A0/xx unknown
- 1999-05-03 KR KR1020007014140A patent/KR20010052817A/ko not_active Application Discontinuation
- 1999-05-03 JP JP2000554368A patent/JP2002518328A/ja active Pending
- 1999-05-03 HU HU0102395A patent/HUP0102395A2/hu unknown
- 1999-05-03 EP EP99914723A patent/EP1085867A1/en not_active Withdrawn
- 1999-05-03 CA CA002335112A patent/CA2335112A1/en not_active Abandoned
- 1999-05-03 SK SK1890-2000A patent/SK18902000A3/sk unknown
- 1999-05-03 CN CN99807381A patent/CN1305378A/zh active Pending
- 1999-05-03 ID IDW20002604A patent/ID26726A/id unknown
- 1999-05-03 AU AU33420/99A patent/AU3342099A/en not_active Abandoned
- 1999-05-07 PA PA19998472101A patent/PA8472101A1/es unknown
- 1999-06-10 AP APAP/P/1999/001581A patent/AP9901581A0/en unknown
- 1999-06-11 UY UY25557A patent/UY25557A1/es not_active Application Discontinuation
- 1999-06-11 PE PE1999000522A patent/PE20000633A1/es not_active Application Discontinuation
- 1999-06-14 GT GT199900083A patent/GT199900083A/es unknown
- 1999-06-15 AR ARP990102847A patent/AR018868A1/es not_active Application Discontinuation
- 1999-06-15 ZA ZA9903973A patent/ZA993973B/xx unknown
- 1999-06-15 TN TNTNSN99118A patent/TNSN99118A1/fr unknown
- 1999-06-15 MA MA25622A patent/MA26648A1/fr unknown
- 1999-06-16 CO CO99037624A patent/CO5070586A1/es unknown
-
2000
- 2000-11-24 IS IS5727A patent/IS5727A/is unknown
- 2000-12-14 NO NO20006381A patent/NO20006381L/no not_active Application Discontinuation
- 2000-12-14 HR HR20000857A patent/HRP20000857A2/hr not_active Application Discontinuation
-
2001
- 2001-01-08 BG BG105128A patent/BG105128A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0102395A2 (hu) | 2001-11-28 |
| PA8472101A1 (es) | 2000-09-29 |
| BG105128A (en) | 2001-11-30 |
| KR20010052817A (ko) | 2001-06-25 |
| IL139587A0 (en) | 2002-02-10 |
| MA26648A1 (fr) | 2004-12-20 |
| CA2335112A1 (en) | 1999-12-23 |
| EA200001189A1 (ru) | 2001-06-25 |
| NO20006381D0 (no) | 2000-12-14 |
| HRP20000857A2 (en) | 2001-10-31 |
| EP1085867A1 (en) | 2001-03-28 |
| AU3342099A (en) | 2000-01-05 |
| SK18902000A3 (sk) | 2001-12-03 |
| IS5727A (is) | 2000-11-24 |
| AR018868A1 (es) | 2001-12-12 |
| ID26726A (id) | 2001-02-01 |
| WO1999065488A1 (en) | 1999-12-23 |
| OA11569A (en) | 2004-07-01 |
| CN1305378A (zh) | 2001-07-25 |
| TNSN99118A1 (fr) | 2005-11-10 |
| PL345064A1 (en) | 2001-11-19 |
| PE20000633A1 (es) | 2000-07-26 |
| CO5070586A1 (es) | 2001-08-28 |
| NO20006381L (no) | 2000-12-14 |
| UY25557A1 (es) | 2001-01-31 |
| JP2002518328A (ja) | 2002-06-25 |
| AP9901581A0 (en) | 1999-06-30 |
| GT199900083A (es) | 2000-12-05 |
| ZA993973B (en) | 2000-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU18400A (sh) | Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja | |
| BR0309875A (pt) | métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto | |
| EA200400735A1 (ru) | 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ | |
| WO2000021926A3 (en) | 6-SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | |
| EE04018B1 (et) | Tieno[2,3-d]pürimidiindioonid, nende valmistamisemeetod ja neid sisaldavad ravimkoostised | |
| PT1222195E (pt) | Novos compostos de tiazolo(4,5-d)pirimidina | |
| BR0100558A (pt) | Composições e métodos para tratar a osteoporose | |
| NO993027D0 (no) | Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler | |
| BR9911357A (pt) | Combinações terapêuticas de moduladores (seletivos) de receptor de estrogênio (serm) e secretagogos de hormÈnio de crescimento (ghs) para tratar fragilidade músculo-esqueletal | |
| CA2325842A1 (en) | Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof | |
| BR9911228A (pt) | Combinações terapêuticas compreendendo um modulador seletivo de um receptor de estrogênio e hormÈnio paratireóide | |
| BR9911324A (pt) | Combinações terapêuticas de moduladores de receptor (seletivo) de estrogênio (serm) e secretagogos de hormÈnio do crescimento (ghs) para o tratamento de fragilidade músculo-esqueletal | |
| BRPI0418887A (pt) | nucleosìdeos de 3-beta-d-ribofuranossiltiazol[4,5-d] pirimidina e usos dos mesmos | |
| BR0112619A (pt) | Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, métodos para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e de distúrbios no sistema nervoso central e/ou de bexiga hiperativa ou vasospasmo ou para o controle do crescimento de tumores | |
| ECSP993021A (es) | Combinaciones terapeuticas para la fragilidad musculoesqueletica | |
| CA2274381A1 (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2 | |
| ECSP993020A (es) | Terapia de combinacion para la fragilidad musculoesqueletica | |
| TH57984A3 (th) | การรวมในทางการรักษาซี่งประกอบด้วยตัวปรับตัวรับเอสโตรเจนแบบคัดเลือกและฮอร์โมนพาราไธรอยด์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |